Wealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Wealth Enhancement Advisory Services LLC has taken a new position in Ultragenyx Pharmaceutical Inc., acquiring 8,848 shares valued at approximately $353,000.
• Analysts have rated Ultragenyx Pharmaceutical with an average rating of "Moderate Buy", with a consensus price target of $81.50.
• Ultragenyx reported earnings of ($1.17) per share for the last quarter, surpassing the consensus estimate, with revenues increasing 13.2% year-over-year to $166.50 million.

Wealth Enhancement Advisory Services LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,848 shares of the biopharmaceutical company's stock, valued at approximately $353,000.

A number of other institutional investors have also added to or reduced their stakes in RARE. GAMMA Investing LLC increased its holdings in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the last quarter. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth $57,000. Headlands Technologies LLC acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth $59,000. Finally, Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 795 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Guggenheim reaffirmed a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Trading Down 1.5%

Shares of NASDAQ RARE opened at $29.74 on Wednesday. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -5.38 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $57.99. The stock has a 50-day moving average price of $29.53 and a two-hundred day moving average price of $33.18.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The business's quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the company's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares of the company's stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.